SURMODICS INC (SRDX) Stock Price & Overview

NASDAQ:SRDX • US8688731004

Current stock price

42.98 USD
+0.15 (+0.35%)
At close:
42.99 USD
+0.01 (+0.02%)
After Hours:

The current stock price of SRDX is 42.98 USD. Today SRDX is up by 0.35%. In the past month the price increased by 52.95%. In the past year, price increased by 9.28%.

SRDX Key Statistics

52-Week Range25.87 - 43.0048
Current SRDX stock price positioned within its 52-week range.
1-Month Range25.87 - 43.0048
Current SRDX stock price positioned within its 1-month range.
Market Cap
614.614M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.24
Dividend Yield
N/A

SRDX Stock Performance

Today
+0.35%
1 Week
+4.98%
1 Month
+52.95%
3 Months
+15.57%
Longer-term
6 Months +49.76%
1 Year +9.28%
2 Years +30.96%
3 Years +18.96%
5 Years +14.80%
10 Years +104.08%

SRDX Stock Chart

SURMODICS INC / SRDX Daily stock chart

SRDX Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to SRDX. When comparing the yearly performance of all stocks, SRDX is one of the better performing stocks in the market, outperforming 77.51% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

SRDX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to SRDX. SRDX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SRDX Earnings

On November 5, 2025 SRDX reported an EPS of 0.06 and a revenue of 29.57M. The company beat EPS expectations (131.46% surprise) and beat revenue expectations (3.32% surprise).

Next Earnings DateJan 28, 2026
Last Earnings DateNov 5, 2025
PeriodQ3 / 2025
EPS Reported$0.06
Revenue Reported29.567M
EPS Surprise 131.46%
Revenue Surprise 3.32%

SRDX Forecast & Estimates

7 analysts have analysed SRDX and the average price target is 43.86 USD. This implies a price increase of 2.05% is expected in the next year compared to the current price of 42.98.

For the next year, analysts expect an EPS growth of 10.36% and a revenue growth -4.48% for SRDX


Analysts
Analysts45.71
Price Target43.86 (2.05%)
EPS Next Y10.36%
Revenue Next Year-4.48%

SRDX Groups

Sector & Classification

SRDX Financial Highlights

Over the last trailing twelve months SRDX reported a non-GAAP Earnings per Share(EPS) of -0.24. The EPS decreased by -172.73% compared to the year before.


Income Statements
Revenue(TTM)120.80M
Net Income(TTM)-17.63M
Industry RankSector Rank
PM (TTM) N/A
ROA -10.38%
ROE -15.84%
Debt/Equity 0.27
Chartmill High Growth Momentum
EPS Q2Q%122.22%
Sales Q2Q%-2.55%
EPS 1Y (TTM)-172.73%
Revenue 1Y (TTM)-0.02%

SRDX Ownership

Ownership
Inst Owners77.38%
Shares14.30M
Float14.23M
Ins Owners0.01%
Short Float %N/A
Short RatioN/A

About SRDX

Company Profile

SRDX logo image Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. The company is headquartered in Eden Prairie, Minnesota and currently employs 389 full-time employees. The company also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the demanding requirements. Its segments include Medical Device and IVD. Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral and coronary. IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.

Company Info

IPO: 1998-03-04

SURMODICS INC

9924 W 74th St

Eden Prairie MINNESOTA 55344 US

CEO: Gary R. Maharaj

Employees: 389

SRDX Company Website

SRDX Investor Relations

Phone: 19525007000

SURMODICS INC / SRDX FAQ

What does SRDX do?

Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. The company is headquartered in Eden Prairie, Minnesota and currently employs 389 full-time employees. The company also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the demanding requirements. Its segments include Medical Device and IVD. Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral and coronary. IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.


What is the current price of SRDX stock?

The current stock price of SRDX is 42.98 USD. The price increased by 0.35% in the last trading session.


Does SURMODICS INC pay dividends?

SRDX does not pay a dividend.


How is the ChartMill rating for SURMODICS INC?

SRDX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Can you provide the number of employees for SURMODICS INC?

SURMODICS INC (SRDX) currently has 389 employees.


What is the ownership structure of SURMODICS INC (SRDX)?

You can find the ownership structure of SURMODICS INC (SRDX) on the Ownership tab.